Hydrocortisone Hualan Pharmaceuticals

Hydrocortisone Hualan Pharmaceuticals is an oral corticosteroid medication whose active ingredient is hydrocortisone. Produced by Hualan Pharmaceuticals and marketed in the European Union, the product is supplied in an unspecified strength and dosage form. As a glucocorticoid, it is used under medical supervision for conditions that require anti‑inflammatory or immunosuppressive therapy. It is classified under ATC code H02AB02 and is intended for prescription use.

Hydrocortisone Hualan Pharmaceuticals is prescribed for several medical conditions that benefit from glucocorticoid therapy.

- Primary adrenal insufficiency (Addison’s disease) requiring replacement therapy. - Acute or chronic inflammatory disorders such as arthritis, dermatitis, or colitis. - Severe allergic reactions, including anaphylaxis, when rapid anti‑inflammatory action is needed. - Certain autoimmune conditions where immunosuppression helps control disease activity. - Pre‑operative or post‑operative management to reduce inflammation and edema. - Management of adrenal crisis in patients with known adrenal insufficiency.

Hydrocortisone may cause a range of adverse reactions, varying from mild and transient to potentially serious.

Common: - Mild gastrointestinal discomfort, such as nausea, dyspepsia, or abdominal cramps, which usually resolves without intervention. - Transient elevation of blood glucose levels, observed more frequently in patients with pre‑existing diabetes or metabolic risk factors. - Fluid retention that may produce mild peripheral edema, particularly in the lower extremities. - Mood alterations including irritability, anxiety, or difficulty sleeping, generally mild and reversible after discontinuation.

Serious: - Severe hyperglycemia or the development of new‑onset diabetes mellitus requiring medical management. - Suppression of the hypothalamic‑pituitary‑adrenal (HPA) axis leading to secondary adrenal insufficiency, especially after abrupt discontinuation. - Increased susceptibility to opportunistic infections such as candidiasis or reactivation of latent viral infections due to immunosuppressive effects.

When prescribing Hydrocortisone Hualan Pharmaceuticals, clinicians should consider several precautionary measures to minimize risk and ensure safe use.

- Assess baseline adrenal function before initiating therapy, especially in patients with known or suspected adrenal insufficiency. - Monitor blood glucose regularly in diabetic patients or those with risk factors for hyperglycemia. - Use the lowest effective dose for the shortest duration possible to reduce systemic exposure. - Evaluate for a history of psychiatric disorders, as glucocorticoids can exacerbate mood or psychotic symptoms. - Consider bone health; long‑term use may increase risk of osteoporosis, so calcium and vitamin D supplementation may be advised. - Avoid abrupt discontinuation; taper the dose gradually to prevent adrenal crisis.

Hydrocortisone can interact with other medicines, altering its effectiveness or increasing the risk of adverse events.

Avoid: - Strong CYP3A4 inducers such as rifampin, phenytoin, or carbamazepine, which may reduce hydrocortisone plasma concentrations. - Concurrent use of high‑dose systemic immunosuppressants (e.g., cyclosporine) without close monitoring, due to additive immunosuppression.

Use with caution: - Anticoagulants (warfarin) – glucocorticoids may enhance anticoagulant effect, requiring INR monitoring. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) – combined use can increase risk of gastrointestinal ulceration or bleeding. - Antidiabetic agents – hydrocortisone may raise blood glucose, necessitating dose adjustments of insulin or oral hypoglycemics. - Vaccines – live attenuated vaccines should be avoided during systemic glucocorticoid therapy.